We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Identification of Malignant Pancreatic Cysts May Lower Cancer Risk

By HospiMedica International staff writers
Posted on 25 Jun 2010
Print article
A new study has identified candidate biomarkers for the diagnosis of pancreatic cystic neoplasms, helping clinicians predict whether the cysts are benign or are precursors to invasive cancer.

Researchers at the University of Michigan (Ann Arbor, USA), Indiana University (Purdue, USA), and the Van Andel Research Institute (VARI, Grand Rapids, MI, USA) used a novel antibody-lectin sandwich microarray method to measure the protein expression and glycosylation of mucin (MUC)1, MUC5AC, MUC16, carcinoembryonic antigen, and other proteins implicated in pancreatic neoplasia in cyst fluid samples. A total of 53 cyst fluid samples were obtained from patients with mucinous cystic neoplasms, intraductal papillary mucinous neoplasms, serous cystadenomas, or pseudocysts, with confirmation of histologic diagnosis at surgical resection.

The results showed that the detection of a glycan variant on MUC5AC discriminated mucin-producing cystic tumors (mucinous cystic neoplasms and intraductal papillary mucinous neoplasms) from benign cystic lesions (serous cystadenomas and pseudocysts) with 78% sensitivity at 80% specificity; when used in combination with cyst fluid CA 19-9, the results were even higher, with a sensitivity of 87% at 86% specificity. The researchers also reported that the biomarkers performed better than cyst fluid carcinoembryonic antigen. The study was published in the May 2010 issue of Annals of Surgery.

"Because of the difficulty in detecting pancreatic cancer in its early stages, most cancers are advanced at the time of diagnosis and recur after removal of the tumor,” said lead author Brian Haab, Ph.D., a senior scientific investigator at VARI. "These results demonstrate the value of glycan variants for biomarker discovery and suggest that these biomarkers could greatly enhance the accuracy of differentiating pancreatic cystic tumors.”

The most common and deadly form of pancreatic cancer, pancreatic ductal adenocarcinomas, develops from three types of cysts. Moreover, although the most prevalent type is too small to be detected visually, cystic lesions of the pancreas are increasingly being recognized due to widespread use of high-resolution abdominal imaging. This situation presents an opportunity to intervene prior to malignant progression; however, effective implementation of this strategy has so far been hampered by difficulties in clearly distinguishing between cystic lesions with no malignant potential and those with malignant potential.

Related Links:

University of Michigan
Indiana University
Van Andel Research Institute


Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Flocked Fiber Swabs
Puritan® patented HydraFlock®
New
Mammography Analytics Platform
Unifi Analytics Software
New
60 SMS Sterilization Wrap
Steri-Wrap Unite

Print article
Radcal

Channels

Critical Care

view channel
Image: The new guideline addresses cardiovascular evaluation and management of patients before, during and after noncardiac surgery (Photo courtesy of Adobe Stock)

New Guideline Details Management of CVD Risk Before, During and After Noncardiac Surgery

There are approximately 300 million noncardiac surgeries performed worldwide each year, highlighting the importance of summarizing and interpreting evidence to help clinicians manage patients undergoing surgery.... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
The Atellica VTLi Patient-side Immunoassay Analyzer, a high-sensitivity troponin I test at the bedside, delivers accurate results in just 8 minutes (Photo courtesy of Siemens Healthineers)

New 8-Minute Blood Test to Diagnose or Rule Out Heart Attack Shortens ED Stay

Emergency department overcrowding is a significant global issue that leads to increased mortality and morbidity, with chest pain being one of the most common reasons for hospital admissions.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.